Dr. Melissa Johnson, MD
Claim this profileSarah Cannon Research Institute
Expert in Non-Small Cell Lung Cancer
Expert in Tumors
59 reported clinical trials
86 drugs studied
About Melissa Johnson, MD
Education:
- Awarded the Morehead-Cain Scholarship at the University of North Carolina, Chapel Hill.
- Obtained an MD (Doctor of Medicine) from the University of Pennsylvania.
Experience:
- Served as Chief Fellow for one year at an unspecified institution.
- Co-founded the Northwestern Medical Developmental Therapeutics Institute.
- Since 2014, has been with the Sarah Cannon Research Institute at Tennessee Oncology, now the Associate Director of Lung Cancer Research.
- Focuses on expanding phase II and III lung cancer clinical trials and developing early-phase compounds for thoracic cancers.
Area of expertise
1Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
EGFR positive
2Tumors
Global LeaderStage IV
Stage III
PD-L1 positive
Affiliated Hospitals
Clinical Trials Melissa Johnson, MD is currently running
BDTX-1535 + Temozolomide
for Glioblastoma and Lung Cancer
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of BDTX-1535. The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma multiforme (GBM) expressing EGFR alterations (Phase 1 only). All patients will self administer BDTX-1535 monotherapy by mouth in 21-day cycles. Phase 1 enrollment is now complete. Phase 2 is currently enrolling.
Recruiting1 award Phase 1 & 214 criteria
IMM-1-104
for Solid Cancers
This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 dose (RP2D) of IMM-1-104 to further explore the anti-tumor activity of IMM-1-104 as monotherapy and in combination with approved agents in multiple Phase 2a proof-of-concept cohorts in malignancies of interest.
Recruiting1 award Phase 1 & 2
More about Melissa Johnson, MD
Clinical Trial Related5 years of experience running clinical trials · Led 59 trials as a Principal Investigator · 28 Active Clinical TrialsTreatments Melissa Johnson, MD has experience with
- Pembrolizumab
- Atezolizumab
- Docetaxel
- Carboplatin
- Nivolumab
- Osimertinib
Breakdown of trials Melissa Johnson, MD has run
Non-Small Cell Lung Cancer
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- BDTX-1535 + Temozolomide for Glioblastoma and Lung Cancer
- Study to Investigate DRP-104 in Adults With Advanced Solid Tumors
Tumors
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- Engineered T-Cell Therapy for Advanced Cancer
- PC14586 for Solid Tumors
Solid Tumors
Lung Cancer
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- BDTX-1535 + Temozolomide for Glioblastoma and Lung Cancer
- HPN328 + Atezolizumab for Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Melissa Johnson, MD specialize in?
Melissa Johnson, MD focuses on Non-Small Cell Lung Cancer and Tumors. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Melissa Johnson, MD currently recruiting for clinical trials?
Yes, Melissa Johnson, MD is currently recruiting for 26 clinical trials in Nashville Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Melissa Johnson, MD has studied deeply?
Yes, Melissa Johnson, MD has studied treatments such as Pembrolizumab, Atezolizumab, Docetaxel.
What is the best way to schedule an appointment with Melissa Johnson, MD?
Apply for one of the trials that Melissa Johnson, MD is conducting.
What is the office address of Melissa Johnson, MD?
The office of Melissa Johnson, MD is located at: Sarah Cannon Research Institute, Nashville, Tennessee 37221 United States. This is the address for their practice at the Sarah Cannon Research Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.